Results 31 to 40 of about 1,901 (143)

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance

MedComm, Volume 7, Issue 4, April 2026.
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng, Feifei Yang, Hongyu Jia, Gan Zhao, Weidong Zhao, Jie Yu, Haoxiang Zhu, Huan Cai, Lishan Yang, Shuren Zhang, Fang Yu, Xiang Jin, Shijie Zhang, Xianzheng Wang, Yida Yang, Jiming Zhang, Bin Wang   +16 more
wiley   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Ocular Immersion Hydrotherapy Effectively Alleviate Symptoms and Signs of Severe Dry Eye Secondary to Ocular Graft‐Versus‐Host Disease in a Short Term

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Purpose To report a novel ocular immersion hydrotherapy (OIH) to manage patients with severe dry eye secondary to ocular graft‐versus‐host disease (oGVHD) and clinical outcomes after treatment. Methods This case series included five consecutive patients with severe oGVHD‐related dry eye who had previously undergone unsuccessful long‐term conventional ...
Haoran Cui, Shuang Zhang, Tao Zhang, Yong Tao, Savvas Lampridis   +4 more
wiley   +1 more source

Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer‐Aided Drug Design

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
This review summarizes the research progress on inhibitors of lumpy skin disease virus (LSDV), focusing on its biological characteristics and key proteins involved in the viral replication cycle. It compiles various inhibitors (direct‐acting poxvirus inhibitors and host‐directed poxvirus inhibitors) against poxviruses, their mechanisms of action, and ...
Leilei ZHAO, Jing QU, Miao AN, Yang LIU, Xiubo LI, Yiming LIU, Chen PENG, Todd R. Callaway   +7 more
wiley   +1 more source

Treatment of Chronic Hepatitis B [PDF]

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2007
Background and objectives:The primary goal of therapy in patients with chronic hepatitis B is durable suppression of HBV DNA to the lowest possible level.
GH Montazeri, MR Ghadir, M Rohban, A Estakhri   +3 more
doaj   +1 more source

C‐6‐Modified 2‐F‐Fucose Derivatives as Inhibitors of Fucosyltransferases

ChemBioChem, Volume 26, Issue 21, November 8, 2025.
A series of C6‐modified guanosine‐diphosphate‐2‐F‐fucose analogs and corresponding prodrugs are designed, synthesized, and biologically evaluated as inhibitors of cellular fucosylation. Certain analogs potently inhibit fucosyltransferases (FUT) FUT1, 3, 6, and 9 while showing minimal activity for FUT8, highlighting the potential for selective FUT ...
Yanyan Liu, Geert‐Jan Boons
wiley   +1 more source

Advancements in the prevention of hepatitis B recurrence by nucleos(t)ide analogue monotherapies after liver transplantation

European Journal of Inflammation, 2022
Previous studies have shown that the recurrence rate of HBV (hepatitis B virus) after liver transplantation (LT) can be as high as 80% without any preventive measures.
Xie Man, Rao Wei
doaj   +1 more source

Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment

Journal of Gastroenterology and Hepatology, Volume 40, Issue 10, Page 2560-2567, October 2025.
ABSTRACT Background and Aim Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited.
Eiichi Ogawa, Motoyuki Kohjima, Toshimasa Koyanagi, Kazufumi Dohmen, Aritsune Ooho, Akira Kawano, Norihiro Furusyo, Eiji Kajiwara, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Yasunori Ichiki, Takeshi Senju, Hiromasa Amagase, Masatake Tanaka, Makoto Nakamuta, Hideyuki Nomura, Jun Hayashi, The Kyushu University Liver Disease Study (KULDS) Group   +19 more
wiley   +1 more source

Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study

Journal of Viral Hepatitis, Volume 32, Issue 9, September 2025.
ABSTRACT Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long‐term therapy, which often leads to nonadherence and increased treatment burden.
Shinya Kawamatsu, Kiran K. Rai, Vera Gielen, Amisha Patel, Olivia Massey, Seth W. Anderson, Yutaka Handa, Ethan Yichen Lee, Poppy Payne, Isabel Jimenez, Kejsi Begaj, Shayon Salehi, Jun Inoue, Afisi S. Ismaila   +13 more
wiley   +1 more source